Search research articles
Contact Us
Filters
Showing results (131-140 of 189) with videos related to
Page
of 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
C Massard, A Plantade, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S Rajpar, C Massard, A Laplanche, et al.
Cancer
|
March 26, 1999
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
T Dorval, S Négrier, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2007
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
K Fizazi, L Morat, L Chauveinc, et al.
The New England Journal of Medicine
|
May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
S Negrier, B Escudier, C Lasset, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
January 13, 2009
[Atypical cysts and cystic tumours of the kidney: histological, radiological and surgical considerations. Conclusions of the AFU 2007 forum]
J-A Long, Y Neuzillet, J-M Correas, et al.
British Journal of Cancer
|
May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, et al.
Biochemical Pharmacology
|
March 23, 1999
Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy
J Elkahwaji, M A Robin, A Berson, et al.
British Journal of Cancer
|
March 6, 2014
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
A Saroufim, Y Messai, M Hasmim, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2010
[Treatment of metastatic kidney cancer in elderly subjects]
B Escudier, P Paparel, Y Neuzillet, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 189) with videos related to
Sort By:
Page
of 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
C Massard, A Plantade, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S Rajpar, C Massard, A Laplanche, et al.
Cancer
|
March 26, 1999
Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
T Dorval, S Négrier, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2007
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
K Fizazi, L Morat, L Chauveinc, et al.
The New England Journal of Medicine
|
May 1, 1998
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
S Negrier, B Escudier, C Lasset, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
January 13, 2009
[Atypical cysts and cystic tumours of the kidney: histological, radiological and surgical considerations. Conclusions of the AFU 2007 forum]
J-A Long, Y Neuzillet, J-M Correas, et al.
British Journal of Cancer
|
May 23, 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, et al.
Biochemical Pharmacology
|
March 23, 1999
Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy
J Elkahwaji, M A Robin, A Berson, et al.
British Journal of Cancer
|
March 6, 2014
Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
A Saroufim, Y Messai, M Hasmim, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 4, 2010
[Treatment of metastatic kidney cancer in elderly subjects]
B Escudier, P Paparel, Y Neuzillet, et al.
Page
of 19